Takeda and PvP Biologics Announce Development Agreement around Novel Therapeutic for Celiac Disease

OSAKA, Japan & SAN DIEGO & SEATTLE–(BUSINESS WIRE)– Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502) and PvP Biologics, Inc. (“PvP”) today announced a global agreement for the development of KumaMax, a novel enzyme designed to break …
( read original story …)


Related Post

Nikkei rises for 6th day as yen weakens; Topix gai...
views 295
TOKYO, Nov 24 Japan's Nikkei share average rose fo...
Japan provides US $700 million to African Developm...
views 149
acknowledged the landmark event and expressed the ...
Japan’s Nikkei closes at highest level in 20 years...
views 222
TOKYO—The Nikkei Stock Average hit a two-decade cl...
Japan's Lesson Tells Italy Capital Alone Won&...
views 288
Fixing a rotten banking sector requires policy mak...
Light earthquake 4.5 mag, 41 km ESE of Namie, Japa...
views 282
A light earthquake magnitude 4.5 (ml/mb) has struc...
The Demise Of The Japanese Financial System
views 290
The BoJ currently conducts a mass nationalization ...
Japan stock market catches overflow from US rally
views 68
TOKYO -- As investor money ebbs from emerging mark...
Japanese Beer Company Raises a Glass for Gay Marri...
views 290
Although Japan does not officially recognize same-...
Stephen Paddock, Las Vegas Suspect, Was a Gambler ...
views 236
His girlfriend, sought for questioning by law enfo...
Nikkei hovers near 2-year highs as tech shares sup...
views 306
TOKYO, June 29 Japan's Nikkei share average rose o...